Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19

Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic.

Bibliographic Details

Main Authors:	Villafañe, Luciana María, Gallo Vaulet, Maria Lucia, Viere, Florencia M., Klepp, Laura Ines, Forrellad, Marina Andrea, Bigi, María Mercedes, Romano, Maria Isabel, Magistrelli, Giovanni, Rodríguez Fermepin, Marcelo, Bigi, Fabiana
Format:	info:ar-repo/semantics/artículo biblioteca
Language:	eng
Published:	Elsevier 2021-12-09T13:43:44Z
Subjects:	COVID-19, Coronavirus del Síndrome Respiratorio Agudo Grave 2, Diagnóstico, ELISA, Técnicas Inmunológicas, Severe Acute Respiratory Syndrome Coronavirus 2, Diagnosis, Immunological Techniques, SARS-CoV-2,
Online Access:	http://hdl.handle.net/20.500.12123/10871 https://www.sciencedirect.com/science/article/pii/S0022175921002271 https://doi.org/10.1016/j.jim.2021.113182
Tags:	Add Tag No Tags, Be the first to tag this record!